Inadequate growth hormone suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' growth hormone levels
Clin Endocrinol (Oxf)
.
2006 Apr;64(4):475-6.
doi: 10.1111/j.1365-2265.2006.02480.x.
Authors
John R Lindsay
,
A Brew Atkinson
PMID:
16584524
DOI:
10.1111/j.1365-2265.2006.02480.x
No abstract available
Publication types
Comment
Letter
MeSH terms
Acromegaly / blood*
Chemotherapy, Adjuvant
Growth Hormone / blood*
Humans
Octreotide*
Patient Selection
Substances
Growth Hormone
Octreotide